In this study, a prolonged preliminary clinical benefit was achieved thanks to anti-PD1 blockade in a PD-L1-positive population of esophageal squamous cell carcinoma and adenocarcinoma, although 52% of the trial population experienced progressive disease (PD) as best response. This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.